Salarius Pharmaceuticals Faces Imminent Nasdaq Delisting; Ineligible for Standard Compliance Period

summarizeSummary

Salarius Pharmaceuticals received a delisting notice from Nasdaq due to its failure to meet the minimum bid price requirement, with delisting scheduled for January 9, 2026, unless an appeal is successful, as the company is ineligible for the standard compliance period.

check_boxKey Events

• Nasdaq Delisting Notice Received

  Salarius Pharmaceuticals received written notice from Nasdaq for non-compliance with the minimum bid price requirement of $1.00 per share (Rule 5550(a)(2)).

• Ineligible for Standard Compliance Period

  The company is not eligible for the typical 180-calendar day compliance period due to a reverse stock split in the prior year and being subject to a Mandatory Panel Monitor.

• Imminent Delisting Threat

  Nasdaq has determined that the company's securities will be scheduled for delisting and suspension from The Nasdaq Capital Market at the opening of business on January 9, 2026, unless an appeal is filed.

• Appeal Intended

  The company intends to appeal the delisting determination by January 7, 2026, which would temporarily stay the suspension and delisting process.

auto_awesomeAnalysis

Salarius Pharmaceuticals received a critical delisting notice from Nasdaq, indicating non-compliance with the minimum bid price requirement. The situation is particularly severe because the company is ineligible for the standard 180-day compliance period, a consequence of a reverse stock split within the past year and being under a Mandatory Panel Monitor. This accelerates the delisting threat, with suspension from Nasdaq scheduled for January 9, 2026, unless a successful appeal is made. While the company intends to appeal, there is no guarantee of a favorable outcome, posing a significant risk to the stock's liquidity and investor confidence, especially as the stock is already trading near its 52-week low.